Argenx Se (ARGX) Other Non-Current Assets (2016 - 2026)
Argenx Se's (ARGX) quarterly Other Non-Current Assets came in at $124.0 million in Q2 2026, down 99.73% YoY from $46.7 billion in Q2 2025, and up 125.45% on a QoQ basis from $55.0 million in Q4 2025.
Argenx Se (ARGX) Other Non-Current Assets (2016 - 2026) Analysis & Trends
Argenx Se (ARGX) has 11 years of Other Non-Current Assets data on file, last reported at $124.0 million in Q2 2026.
- Quarterly Other Non-Current Assets fell 99.73% year-over-year to $124.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $124.0 million (down 99.73% YoY) and the FY2025 annual result came in at $55.0 million, up 29.74% from the prior year.
- Other Non-Current Assets grew to $124.0 million in Q2 2026, from $55.0 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $46.7 billion in Q2 2025 to a low of $34.3 million in Q2 2024.
- A 5-year average of $5.2 billion and a median of $42.4 million in 2024 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2025 — Other Non-Current Assets surged 136097.34% — and 2026, when it tumbled 99.73%.
- Tracing ARGX's Other Non-Current Assets over 5 years: stood at $40.9 million in 2022, then decreased by 3.01% to $39.7 million in 2023, then rose by 6.89% to $42.4 million in 2024, then rose by 29.74% to $55.0 million in 2025, then surged by 125.45% to $124.0 million in 2026.
- The last three Other Non-Current Assets figures came in at $124.0 million (Q2 2026), $55.0 million (Q4 2025), and $46.7 billion (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 29.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 124.00 Mn |
| Dec 31, 2025 | 55.00 Mn |
| Jun 30, 2025 | 46.68 Bn |
| Dec 31, 2024 | 42.39 Mn |
| Jun 30, 2024 | 34.28 Mn |
| Dec 31, 2023 | 39.66 Mn |
| Jun 30, 2023 | 39.23 Mn |
| Dec 31, 2022 | 40.89 Mn |
| Jun 30, 2022 | 43.10 Mn |
| Dec 31, 2021 | 54.88 Mn |
| Jun 30, 2021 | 1.44 Mn |
| Dec 31, 2020 | 7.61 Mn |
| Jun 30, 2020 | 696,122.80 |
| Dec 31, 2019 | 3.57 Mn |
| Jun 30, 2019 | 400,015.52 |
| Dec 31, 2018 | 287,631.90 |
| Jun 30, 2018 | 2.02 Mn |
| Dec 31, 2017 | 301,422.73 |
| Jun 30, 2017 | 1.86 Mn |
| Dec 31, 2016 | 1.24 Mn |